PROTID, the first phase 3 RCT examining TB prevention among people with TB with ancillary studies on screening, diagnosis, quality of care and cost- and epidemiological impact, was started in 2019, as part of the EDCTP2 programme supported by the European Union. Due to the COVID-19 pandemic, PROTID suffered significant delays. But as part of the Global […]
Read moreProf. Reinout Van Crevel (Radboudumc, The Netherlands) and Dr. Irene Andia-Biraro (Makerere University, Uganda) presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which took place as a hybrid event, both online and in Copenhagen-Denmark. Prof. Reinout gave a talk on “Host-pathogen interactions and immunotherapy in mycobacterial infections” co-organised with the […]
Read moreThe PROTID (Preventive Treatment of Latent Tuberculosis Infection in people with Diabetes Mellitus) project addresses a key EDCTP prevention priority area, namely TB and comorbidities. In 2022 we initiated the first randomized controlled trial globally that evaluates the efficacy and impact of preventive treatment of latent tuberculosis infection (LTBI) in people living with diabetes. On […]
Read moreAnother insightful publication from our consortium. This review highlights gaps in the incomplete understanding of the mechanisms that may relate to TB susceptibility in type 2 DM (T2DM). Understanding these three main domains regarding mechanisms of TB susceptibility in T2DM patients can help us build practical treatment plans to lessen the combined burden of the […]
Read moreThis systematic review from our Ugandan PROTID colleagues demonstrates that the availability of essential medicines and diagnostic tests for diabetes in Africa is suboptimal. The relatively high cost of insulin, HbA1c, and lipid profile tests forms a significant barrier to optimal diabetes care. The article advocates pragmatic country-specific strategies to address these inequities in access […]
Read moreAnother great PROTID collaboration: this systematic review and meta-analysis documented the proportion of attainment of optimal HbA1c, blood pressure and low-density lipoprotein cholesterol (LDLC) goals and the prevalence of five diabetes complications (diabetic peripheral neuropathy, nephropathy, retinopathy, foot ulcers and peripheral arterial disease) in adult native populations with type 2 diabetes in Africa. Please access […]
Read moreIn June 2022 the first participants were enrolled in the PROTID study. After succesful Site Initiation Visits performed by the study Sponsor (NIMR-MMRC, Mbeya, TZA), all sites were able to start enrolment by June. See for a full description of the study protocol: Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): […]
Read moreWe are pleased to announce that the meeting report of the technical consultation on innovative clinical trial designs for evaluating new TB preventive treatments is now online: Report of the technical consultation on innovative clinical trial designs for evaluating new TB preventive treatments, virtual meeting, 15-17 September 2021 (who.int) The World Health Organization (WHO) Global […]
Read more
From 15 to 17 September 2021, the WHO Global Tuberculosis Program, in collaboration with University College London and others partners had a virtual technical consultation. The consultation focused on the Innovative Clinical Trial Designs for the evaluation of new TB preventive treatments. PROTID was present during this technical consultation and was represented by Reinout van […]
Read moreOn August 26th and September 23rd, PROTID and all her partners held their Semi-Annual meeting remotely to discuss the current state of business and the upcoming trial. With the delays over the last year due to the COVID-19 pandemic, the work towards the project’s objectives has been challenging for all partners. We are optimistically looking […]
Read more
